Showing 5961-5970 of 8784 results for "".
- Skin Cancer Foundation Hosts Young Professionals Partyhttps://practicaldermatology.com/news/skin-cancer-foundation-hosts-young-professionals-party/2458943/The Skin Cancer Foundation hosted its 2015 Young Professionals Party in New York City on Thursday, May 14 at the Press Lounge rooftop bar at the Ink 48 Hotel. The event united more than 300 young professionals from the beauty and medical industries in the fight a
- R. Scott Peterson Is New Head of Medical Affairs at SkinCeuticalshttps://practicaldermatology.com/news/r-scott-peterson-is-new-head-of-medical-affairs-at-skinceuticals/2458946/R. Scott Peterson, PhD has been named Head of Medical Affairs at SkinCeuticals. In his new role at SkinCeuticals, Dr. Peterson will lead the medical affairs team and expand regional scientific services to support the realization of the company's miss
- Murad Partners with AAD to Launch Shade America Programhttps://practicaldermatology.com/news/murad-partners-with-aad-to-launch-shade-america-program/2458951/Murad, Inc. partnered with the American Academy of Dermatology (AAD) to launch Shade America, a new program that will build shade structures in parks and playgrounds across America to provide shade from the sun’s harmful rays. Through the Shade America program, Murad’s goal is to prov
- Foamix Pharmaceuticals Ltd. Closes Its $69 Million Public Offering of Ordinary Shareshttps://practicaldermatology.com/news/foamix-pharmaceuticals-ltd-closes-its-69-million-public-offering-of-ordinary-shares/2458956/Foamix Pharmaceuticals Ltd. closed its follow-on public offering. A total of 7,419,353 ordinary shares were sold at a price to the public of $9.30 per share. Prior to closing, the underwriters fully exercised their option to purchase 967,741 additional ordinary shares. The net proceeds from the s
- Merck's Pembrolizumab Demonstrates Positive Results in Phase III Study for Advanced Melanomahttps://practicaldermatology.com/news/mercks-pembrolizumab-demonstrates-positive-results-in-phase-iii-study-for-advanced-melanoma/2458959/Merck announced results from the randomized, pivotal Phase III study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, pembrolizumab was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).
- FDA Clears Syneron Candela's PicoWay Picosecond Laser for Treatment of Pigmented Lesionshttps://practicaldermatology.com/news/fda-clears-syneron-candelas-picoway-picosecond-laser-for-treatment-of-pigmented-lesions/2458961/The FDA cleared Syneron Medical Ltd.’s PicoWay® picosecond laser for the treatment of pigmented lesions. The PicoWay picosecond laser previously received FDA clearance for the removal of tattoos in November 2014 and was launched in the US late in the fourth quarter 2014. PicoWay
- Provectus Biopharmaceuticals, Pfizer Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancerhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-pfizer-receive-patent-allowance-for-use-of-pv-10-in-combination-with-systemic-immunotherapy-agents-in-treatment-of-cancer/2458962/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, announced today that it has received from the US Patent and Trademark Office a N
- RXi Pharmaceuticals Receives FDA Orphan Drug Designation for Samcyprone for Melanomahttps://practicaldermatology.com/news/rxi-pharmaceuticals-receives-fda-orphan-drug-designation-for-samcyprone-for-melanoma/2458964/The FDA granted RXi Pharmaceuticals Corporation Orphan Drug Designation of its second clinical candidate, Samcyprone™, for the treatment of malignant melanoma Stage IIb to IV. A number of patients with Stage IIb to IV malignant melanoma develop cutaneous metastases. Samcyprone™ is bei
- Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agenthttps://practicaldermatology.com/news/provectus-opens-phase-3-trial-enrollment-for-investigational-melanoma-agent/2458965/Provectus Biopharmaceuticals, Inc. has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The study is an international multicenter, open-label, randomized controlled trial of single-agent intralesional PV-10 versus systemic chemother
- Association of Dermatology Administrators and Managers Names Alice Hyman “Practice Manager of the Year”https://practicaldermatology.com/news/association-of-dermatology-administrators-and-managers-names-alice-hyman-practice-manager-of-the-year/2458966/The Association of Dermatology Administrators and Managers (ADAM) named Alice Hyman of Advanced DermCare in Danbury, CT, the recipient of this year’s Practice Manager of the Year award. She was recognized at the 23rd annual ADAM meeting in San Francisco. Ms. Hyma